Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy

Exclusion Criteria

• •Participants should not be enrolled if they cannot be treated in accordance with the local product label
• •Participants enrolled into another study or clinical trial
• •History of hepatitis B infection
• •History of neurologic symptoms suggestive of central nervous system demyelinating disease
• •History of cancer or lymphoproliferative disease (other than successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix)
• •Active tuberculosis infection before initiating adalimumab treatment or latent tuberculosis infection not able to take complete prophylactic treatment
• •Pregnant or lactating female, demonstrated by a pregnancy test before entering the study and willing to use a contraceptive method
• •Use of another anti-tumoral necrosis factor previously
• •History of congestive heart failure
• •Any other condition that according to the criteria of the participating investigator represents an obstacle for study conduction and/or subjects participants to an unacceptable risk
• •Participants with active infection including chronic or localized infections until infections are controlled
• •History of sensitivity to latex
• •Participants who will receive concomitant phototherapy and systemic therapy during adalimumab therapy